All News

ILD.colors

RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest

Jiha Lee, MD

At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.

Read Article
EULAR.Docs.APP

Day 2 Report from EULAR 2026

Jack Cush, MD

Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease.  Here are a few of my favorites from Day 2. 

Read Article
elderly hands

A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology

Jiha Lee, MD

A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.

Read Article
manpower.cliff.shortage

Rheumatology Shortage Cliff in Australia & USA

Jack Cush, MD

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.

Read Article
RA,polyarticular,black,rheumatoid

ACPA and the Transition from Arthralgia to Rheumatoid Arthritis

MedPage Today

Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for anti-citrullinated protein antibodies (ACPA), researchers found.

Read Article
PsA.Xray_.Erosion.Cup_.jpg

Guselkumab gets FDA Nod for X-ray Protection

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Read Article
TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190 https://t.co/4yjD9CmySM
Dr. John Cush RheumNow ( View Tweet)
#EULAR2026 Signing off from the conference 🚆. A lot of learning points and things to consider for tomorrow’s practice, caught up with colleagues and formed new collaborations. Thank you @eular_org. Hope you enjoyed our @RheumNow coverage. See you in Berlin 🇩🇪 #EULAR2027 https://t.co/nyaBnHLrxr

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis. @ElenaNikiUK @RheumNow #EULAR2026 https://t.co/UmB63QBl7N

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
How many ‘cars’ are there? crowded #CAR-T ‘driving’ innovation at #EULAR2026 >90 abstracts w CAR-T in title Lessons learned Maybe #immune #reset is not always the goal ➡️vs ’#immune #dimming How long are effects? safety looks good PT selection is key Early, no damage @RheumNow https://t.co/6jii5MBJcJ

Links:

Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

Digitalization in rheumatology. How can it help? Potential opportunities @RheumNow #EULAR2026 https://t.co/KKImSNLgbq

Links:

Bella Mehta bella_mehta ( View Tweet)
🩺🌳When good clinical practice meets reducing environmental burden of healthcare: Rheumatologists can do a lot! Less is more ⬇️ Thank you @eular_org for planning environmental awareness sessions Looking forward to #greener congresses #EULAR2026 @RheumNow https://t.co/5FwARRi92m

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Another reason for NOT prescribing ANA (and other tests) as a “screening” test when not indicated: High carbon footprint! #EULAR2026 @rheumnow https://t.co/BAuzQuZ0Iv

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Have you ever thought of diclofenac as an environmental pollutant? Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026 @rheumnow https://t.co/RJWB6DmiZh

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Getting #RA and IA diagnosed faster: UK RheumACaN program (integrated education + pathway redesign) ↑ clinician confidence 4.4 to 8.6/10. Referral within 3 days: 52% → 70%, with sustained improvement. Education that translates to real outcomes. @RheumNow #EULAR2026 POS0784 https://t.co/1Va9rkLBHM

Links:

Jiha Lee JihaRheum ( View Tweet)
Proud to present POS0784 at #EULAR2026. RheumACaN education + pathway redesign across primary and secondary care improved early inflammatory arthritis referrals within 3 working days from 52% to 70%, exceeding the national benchmark. 95% of clinicians changed their practice. https://t.co/W6VViVRndp

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#OP0114 at #EULAR2026: Spanish study finds marked regional disparities in premature mortality from systemic connective tissue diseases. Higher socioeconomic deprivation and longer waits for specialist care were both linked to worse outcomes. @RheumNow https://t.co/04we2H0wdb

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
In the cross-sectional study of US SLE patients, what was the most common drug class driving polypharmacy beyond SLE medications? Test your knowledge in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/ox4rGp04WH

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×